oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Search Results: 1 - 10 of 899 matches for " Tandon Vishal "
All listed articles are free for downloading (OA Articles)
Page 1 /899
Display every page Item
Paradigm Shift in the endocrine therapy for postmenopausal women with advanced breast cancer
Dr Vishal,R. Tandon
Pharmaceutical Reviews , 2005,
Abstract: For many years, tamoxifen has been the 'gold standard' amongst anti-oestrogen therapies for breast cancer, through its ability to antagonize estrogen-dependent growth by binding estrogen receptors (ERs) and inhibiting proliferation of breast epithelial cells. However, tamoxifen has estrogenic agonist effects in other tissues such as bone and endometrium due to liganded ER activating target genes in these different types of cell. Several novel anti-estrogen compounds have been developed which have a reduced agonist profile on breast and gynecological tissues.These compounds offer the potential for enhanced efficacy and reduced toxicity compared with tamoxifen. In advanced breast cancer clinical data exist for the selective estrogen receptor modulators (SERMs), But, the selective oestrogen receptor modulators (SERMs), such as toremifene, droloxifene, idoxifene, raloxifene, and arzoxifene, show minimal activity in tamoxifen-resistant disease and show no superiority over tamoxifen as first-line treatments. In addition to these agents, other treatment options for advanced disease include high-dose oestrogens and progestins. Response rates for high-dose oestrogens and tamoxifen are similar, but the use of oestrogens is limited by their toxicity profile. (1) Hence there is need of drugs with better clinical; profile for the treatment of breast cancer. Aromatase inhibitors and SERDS are new introductions in this field which are discussed in the present review.
Antioxidants : Past And Present
Dr Vishal Tandon
Pharmaceutical Reviews , 2005,
Abstract: The role of oxidative stress is well recognized now in numerous pathological states, where antioxidants can play very important role. Recent studies provide evidences that low levels of antioxidants are associated with increased risk for many pathological states and that increased intake appears to be protective. However, there are conflicting studies also, that question the rationale for antioxidant supplementation in these conditions by suggesting detrimental effects to the health. Suicidal oxidative stress produced by some of the antioxidants under certain circumstances remains the major cause of concern ,as many antioxidants can act as pro-oxidants in certain conditions. Moreover, at present there are number of unanswered questions associated with practical application of antioxidant therapy like appropriate timing of administration, dose & duration of therapy, which still need to be determined. Inspite of these concerns, antioxidant therapy has gained an important status presently in the prevention and treatment of various pathological conditions. However, under the shadow of these concerns, the supplementation of natural dietary antioxidant resources seems to be a safe and effective approach currently.KEY WORDS : Oxidative stress, antioxidants, present, past, status.
Pharmacotherapy to Improve Sexual Health after Menopause
Vishal Tandon,Sudhaa Sharma
Pharmaceutical Reviews , 2005,
Abstract: Sexual problems are among the most frequently presented health concerns of women attending menopause clinics. For some women, but by no means all, menopause brings a decrease in sexual activity. Common sexual complaints include loss of desire, decreased frequency of sexual activity, painful intercourse, diminished sexual responsiveness, and dysfunctions of the male partner. Sexual function is influenced not only by biologic but also by nonbiologic factors. Medical management of female sexual dysfunction so far is primarily based on hormone replacement therapy.Psychosexual therapy and other sex therapy techniques can be very useful. Hence those women who have always enjoyed the emotional and physical intimacy that love-making brings in their young age, there is absolutely no reason whatsoever, medical or otherwise, why the menopause should deprive them of sexual pleasure.Key words:Sex, Menopause, HR
Current management of Osteoarthritis
Vishal Tandon,Annil Mahajan.
Pharmaceutical Reviews , 2005,
Abstract: Osteoarthritis (OA) is a chronic degenerative disorder of multifactorialetiology characterized by loss of articular cartilage and periarticular boneremodelling. OA causes joint pain, typically worse with weight-bearing and activityas well as can manifest with stiffness after inactivity. It can present as localized,generalized or as erosive osteoarthritis. Primary osteoarthritis is mostly relatedto aging, whereas, secondary osteoarthritis is caused by another disease orcondition. X-rays, arthrocentesis and arthroscopy remain the main diagnostictools. Blood tests are performed to exclude diseases that can cause secondaryosteoarthritis. The treatment of osteoarthritis include non-pharmacologicalmanagement, pharmacological treatment in the form ofdrugs which canmodify symptoms, symptomatic slow acting drugs for OA or structure modifyingOA drugs depending upon the clinical requirement of the patient. Patients withpersistent pain and progressive limitation of daily activities despite medicalmanagement may be the candidates for surgery.
Effect of Vitex negundo on oxidative stress
Tandon Vishal,Gupta R
Indian Journal of Pharmacology , 2005,
Abstract:
Nobel Hiv-1 Protease Inhibitors
Dr. Vishal R.Tandon
Pharmaceutical Reviews , 2005,
Abstract: The HIV protease is essential for viral infectivity and cleaves the viral polyprotein(gag-pol) into active viral enzymes (reverse transcriptase, protease and integrase)and structural proteins. Thus, protease enzyme involved in the production ofstructural proteins and enzymes of virus as well as for maturation of new viralparticle. All available protease inhibitors act by binding reversibly to theactive site of HIV protease. This prevents the protease from cleaving the viralprecursor polypeptide and blocks subsequent viral maturation1. Resistanceto these agents is generally by stepwise accumulation of mutations of the proteasegene and is growing rapidly1. Therefore, there is always a need fornewer protease inhibitors for the effective treatment of HIV infections. Atazanvirand fosamprenavir are two recently approved HIV-1 protease inhibitors.Atazanavir,( BMS-232632)2-5: is a type of antiretroviral agent called a protease inhibitor (PI). It blocks protease, a protein that HIV needs to make more copies of it. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Atazanavir does not care HIV or prevent passing HIV to others.
Scrub Typhus-Reemergence in Jammu
Annil Mahajan, Vishal R. Tandon
JK Science : Journal of Medical Education & Research , 2010,
Abstract: NA
Prescription Mistakes In Rheumatology Practice
Vishal R Tandon, Annil Mahajan*
JK Science : Journal of Medical Education & Research , 2010,
Abstract: Not available
Rheumatic Disorders - A Rural Experience
Vishal .R. Tandon*, Annil Mahajan
JK Science : Journal of Medical Education & Research , 2007,
Abstract: Not available
HIV/AIDS-TB Co-Infection:
Annil Mahajan, Vishal R. Tandon*
JK Science : Journal of Medical Education & Research , 2007,
Abstract: Not available
Page 1 /899
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.